
Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …

An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

